GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Forward Dividend Yield %

ENZN (Enzon Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Dec. 11, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Forward Dividend Yield %?

As of today (2024-12-11), the Forward Annual Dividend Yield of Enzon Pharmaceuticals is 0.00%.

As of today (2024-12-11), the Trailing Annual Dividend Yield of Enzon Pharmaceuticals is 0.00%.

ENZN's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.47
* Ranked among companies with meaningful Forward Dividend Yield % only.

Enzon Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Enzon Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Enzon Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's Forward Dividend Yield % falls into.



Enzon Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Enzon Pharmaceuticals  (OTCPK:ENZN) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Enzon Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121

Enzon Pharmaceuticals Headlines

From GuruFocus

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-09-2010

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010

Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals

By Sydnee Gatewood Sydnee Gatewood 12-02-2016

Enzon Pharmaceuticals Announces Key Dates for Rights Offering

By Marketwired Marketwired 09-16-2020

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009

Enzon Inc. (ENZN) Exec VP Finance, CFO Craig A Tooman sells 123,100 Shares

By GuruFocus Research GuruFocus Editor 06-22-2010

Enzon Pharmaceuticals Announces Results of Rights Offering

By Marketwired Marketwired 10-22-2020